Jul 14, 2021 / 03:00PM GMT
Matthew Kaplan - Ladenburg Thalmann & Co. Inc. - Analyst
Good morning. It's my pleasure to introduce our next presenting company, Avadel. Presenting for the company is Greg Divis, CEO. And Greg, we look forward to this chat -- fireside chat that we are going to have.
Questions and Answers:
Matthew Kaplan - Ladenburg Thalmann & Co. Inc. - AnalystAnd I want to kick it off with -- I guess for people that aren't familiar with Avadel, can you give us a little bit of a brief background on the Company and your overall vision for the Company as well?
Greg Divis - Avadel Pharmaceuticals plc - CEO
Yes, Matt. First of all, thanks for the opportunity to be here and the chance to participate in your conference. We really greatly appreciate it. Avadel is a biopharmaceutical company that is primarily focused today on the development of our investigational, once-nightly-at-bedtime FT218, which is our once-nightly formulation of sodium oxybate for patients suffering from narcolepsy and specifically patients suffering